Live Q&A: Multidisciplinary Management of GLP-1 RAs in T2D and Associated Syndromes

A major hurdle in managing type 2 diabetes (T2D) is a widespread gap in clinician awareness around the powerful, far-reaching benefits of GLP-1 receptor agonists (GLP-1 RAs). These innovative therapies help reduce the burden of cardiovascular, kidney, and metabolic (CKM) syndromes, offering a game-changing opportunity to elevate patient care. Targeted and evidence-based education is crucial to empower clinicians and multidisciplinary care teams with practical strategies for patient selection and personalized therapy, especially when managing patients with complex comorbidities. Deepening clinical understanding and confidence will position GLP-1 RAs as a pillar of T2D treatment and drive better outcomes for patients with T2D and associated CKM complications.

In this CME Outfitters live Q&A, expert faculty will answer questions about the multifaceted impact of GLP-1 RA therapies on glycemic control, CV health, weight management, renal health, liver health, and overall T2D complication risk.

At the conclusion of this activity, learners will be able to better:

• Identify the multifaceted impact of GLP-1 RA therapies on glycemic control, CV health, weight management, renal health, liver health, and overall T2D complication risk
• Differentiate current and emerging GLP-1 RA therapies based on their dosing schedules, administration methods, and glycemic and extra-glycemic benefits
• Identify the mechanisms of action (MOAs) of GLP-1 RAs including their effects on key organ systems, including the pancreas, liver, brain, kidneys, and CV system
• Incorporate clinical trial evidence supporting the use of GLP-1 RAs in T2D management, including outcomes related to glucose control, CV safety, CKD, and tolerability
• Utilize current treatment guidelines to implement GLP-1 RA therapy tailored to individual patient characteristics, including comorbidities, goals of care, and lifestyle considerations
• Individualize the selection of GLP-1 RA therapies based on patient-specific factors such as CV risk, weight management needs, and preferences for administration
• Assess dosing strategies and escalation best practices to optimize patient outcomes and foster therapy adherence
• Develop patient-centered counseling strategies that address concerns or misconceptions of GLP-1 RA therapies, including evidence-based benefits
• Integrate specific resources on AE mitigation and expectations as part of regular counseling for patients treated with GLP-1 RAs to improve adherence
• Integrate GLP-1 RAs into a broader T2D management plan by detecting and addressing barriers to access and optimal utilization

Supported by an educational grant from Novo Nordisk Inc.

Primary care physicians (PCPs), physician associates (PAs), nurse practitioners (NPs), and pharmacists

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Rothberg reports the following financial relationships:

Grants: Boehringer Ingelheim

Dr. Shubrook reports the following financial relationships:

Advisory Board: Abbott; Bayer; Insulet Corporation; Lilly; Madrigal Pharmaceuticals, Inc.; Novo Nordisk; and Sanofi

Consultant: Abbott; Bayer; Novo Nordisk; and Sanofi

Grants: Breakthrough T1D

The following individuals have no financial relationships to disclose:

Thai Nguyen, MD, MHA (Peer Reviewer)
Shirley Michelle Franks, MSN, APRN, FNP-BC (Peer Reviewer)
Keshia Pitt, PhD (Planning Committee)
Carrie Allen, PharmD, BCPS (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

*All identified conflicts of interest have been mitigated.

Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (0% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Call us at 877.CME.PROS (877.263.7767).

SNQ-268-111325-68